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Purpose: To report the use of corneal collagen crosslinking in the treatment of infective keratitis 
not responding to antimicrobial therapy.
Methods: Two retrospective case reports of infective keratitis treated with corneal collagen 
crosslinking.
Results: In both cases, corneal collagen crosslinking caused a rapid resolution of the infective 
keratitis, leaving residual stromal scarring. Due to the density of scarring, one case required 
subsequent penetrating keratoplasty for visual rehabilitation.
Conclusion: Corneal collagen crosslinking is a promising new technique for the management 
of infective keratitis not responding to antimicrobial therapy. Further elucidation of its safety 
and role in management of infectious keratitis is needed by way of future studies.
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Introduction
Ulcerative keratitis is a sight-threatening condition, which requires skilled management 
and effective chemotherapy to preserve vision. If appropriate antimicrobial treatment 
is delayed, it is estimated that only 50% of eyes heal with good visual outcome.1
The treatment of corneal ulcers with topical antimicrobial agents has been con-
founded by the ability of microbes to develop resistance to the drugs used. There is 
therefore a need for an agent which provides complete, rapid antimicrobial activity 
with a minimum of toxicity.
Riboflavin and ultraviolet light (UV) collagen crosslinking of the cornea induces a 
change in properties of the collagen and has a stiffening effect on the corneal stroma, 
which stabilizes it and increases its resistance to enzymatic degradation.2,3
Although corneal collagen crosslinking was originally introduced as a treatment 
for corneal ectasia by Wollensak et al4,5 it has been used in the treatment of a variety 
of other conditions such as symptomatic Fuch’s corneal dystrophy,6 pseudophakic 
bullous keratopathy,7 and more recently, infectious keratitis.8–11
These two case reports describe the authors’ experience with corneal collagen 
crosslinking for the treatment of infectious keratitis.
Case 1
A 30-year-old lady presented at Magrabi Eye Hospital as a referral from a local oph-
thalmologist with a 2-week history of pain, redness, and decreased vision in her right 
eye. The referring ophthalmologist had diagnosed her as having bacterial keratitis 
in her right eye. Culture and sensitivity results showed Staphylococcus aureus to be 
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the causative microorganism. Treatment had already been 
  initiated with intensive topical fortified antibiotic therapy 
with hourly fortified cefuroxime drops (5%) together with 
hourly fortified gentamicin drops (1.5%). However, in spite 
of initial sensitivities showing susceptibility to these antibiot-
ics, the infection had progressed.
Best-corrected visual acuities (BCVAs) were finger 
counting at 1 meter in the right eye and 20/20 in the left 
eye. Ocular examination showed an elliptical, central area of 
corneal infiltration, 4 mm × 2 mm in diameter (Figure 1A). 
A moderate anterior chamber reaction of more than two cells 
was seen, and no hypopyon. The conjunctiva was congested, 
but no purulent discharge was seen.
Medications were stopped for 24 hours, after which cor-
neal scraping was repeated to obtain material for Gram and 
Giemsa slides, together with culture and sensitivity plating. 
The fortified gentamicin 1.5% and cefuroxime 5% drops 
were recommenced. However, gram stain and cultures 
yielded no result.
A week later, the corneal abscess appeared to have 
increased in size. The risks of progression and corneal perfo-
ration, if treatment continued with conservative management, 
were weighed against the possible benefits of decreasing the 
load of pathogen with UV irradiation were discussed with 
the patient, after which the decision was made to proceed 
with UVA-riboflavin collagen crosslinking.
Topical anesthesia was achieved using 0.4% benoxinate 
drops. Epithelium was not removed as there was already 
a large epithelial defect overlying the abscess. Riboflavin 
drops (Medio-Cross® riboflavin/dextran solution, 0.1%) were 
instilled topically to the cornea for a period of 20–30   minutes 
at an interval of 2–3 minutes. The cornea was then illuminated 
using a UVX lamp (PeschkeMeditrade GmbH, Huenenberg, 
Switzerland), UVA 365 nm, with an irradiance of 3 mW/cm2 
and a total dose of 5.4 J/cm2.
During the period of UV illumination, riboflavin was 
administered to the right eye at the same interval.   Following 
this, treatment with gentamicin 1.5% and cefuroxime 
5% drops was recommenced. Topical corticosteroids were 
not prescribed after the crosslinking procedure.
Follow-up examination at 1 week showed that the abscess 
had reduced in size to 2 mm in diameter and its margins were 
better defined. The epithelial defect overlying the abscess 
was also smaller. The patient also stated that she felt less 
pain. The medication was tapered at this point bringing 
the frequency of antibiotic drop instillation down to every 
2 hours during the day.
Two weeks after crosslinking, the corneal abscess and epi-
thelium had completely healed, with a residual scar remaining 
(Figure 1B). A demarcation line was clearly visible in the 
cornea adjacent to the corneal abscess (Figure 1C). BCVA 
improved to 20/100. Fortified antibiotic drops were discon-
tinued and replaced by fluorometholone 0.1%/  gentamicin 
0.3% (Infectoflam, Novartis Pharma AG, Basel, Switzerland) 
drops twice daily for 1 month. At 2 months, the BCVA was 
20/40, the infection had completely resolved, but vision was 
impaired by a central corneal scar (Figure 1D).
Case 2
A 47-year-old laborer was referred to Magrabi Eye Hospital 
from another city after having been unsuccessfully treated for 
fungal keratitis at another hospital. He gave a vague history 
of some debris entering his eye while working a month back. 
After corneal scraping for Gram staining, Giemsa staining, 
and culture plating, he had initially been placed on hourly 
ciprofloxacin 0.3% eye drops. These had been changed to 
amphotericin 2 mg/mL eye drops after Sabouraud agar grew 
Aspergillus as a causative organism.
Visual acuities were hand motion in the right eye with 
accurate light projection and 20/20 in the left eye. Ocular 
examination showed a large corneal abscess measuring 9 mm 
horizontally by 7 mm vertically (Figure 2A). Temporally, the 
abscess was approaching the limbus. The bulbar and forniceal 
conjunctiva showed some patches of necrosis from prolonged 
amphotericin B treatment. Initial corneal scrapings yielded 
no hyphae, but a subsequent corneal biopsy confirmed the 
diagnosis of Aspergillus spp.
Considering the large size of the abscess and its prox-
imity to the limbus, a therapeutic penetrating keratoplasty 
(PKP) was felt to be the most appropriate management. 
Figure  1  Appearance  of  case  1  (A)  at  initial  presentation,  (B)  2  weeks  after 
crosslinking, (C) 2 weeks after crosslinking (note the stromal demarcation line due 
to crosslinking, adjacent to the abscess), and (D) 2 months after crosslinking.
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However, given the poor outcomes of corneal grafting 
  procedures in infectious keratitis, UVA-riboflavin crosslink-
ing was performed in an attempt to decrease the fungal load 
in the corneal abscess. Treatment with hourly amphotericin 
2 mg/mL eye drops was continued after the procedure. No 
topical corticosteroids were prescribed. One week after cross-
linking, the corneal abscess appeared to have better-defined 
margins and less infiltration than before (Figure 2B). The 
epithelial defect appeared slightly smaller. Amphotericin 
drops were gradually tapered over the coming weeks.
Two months after crosslinking, the abscess had been 
replaced by scar tissue. The lesion diameter had decreased 
to 3 mm. Superficial and deep stromal blood vessels were 
encroaching on the central cornea, causing an intra-abscess 
bleed (Figure 2C). By this point, the corneal epithelium 
had healed over the abscess. Amphotericin drops were 
discontinued.
Four months after crosslinking, penetrating kerato-
plasty combined with extracapsular cataract extraction and 
intraocular lens implantation was performed, uneventfully 
(Figure 2D). BCVA 6 months after the graft was 20/50, with 
a manifest refraction of −2−4 × 85.
Discussion
The case reports presented here show that corneal collagen 
crosslinking has two possible roles in the treatment of infec-
tious keratitis not responding to antibiotic therapy.
Firstly, the antimicrobial properties of UVA radiation 
destroy pathogenic microorganisms in the cornea, aid-
ing resolution of the keratitis. Secondly, the crosslinking 
helps avoid an emergency penetrating keratoplasty with its 
  associated high risks of graft rejection. The reported rates 
of graft rejection after therapeutic PKP range from 14.6% to 
52% in various reported series.12–14 A 26% graft failure rate 
after rejection in therapeutic PKPs was reported by Hill.15
Tsugita et al16 showed that exposing riboflavin to UV 
light caused a deactivation of the ribonucleic acid (RNA) 
tobacco mosaic virus. Since then, research has been done to 
look into the possibility of using riboflavin as a photosen-
sitizer to deactivate pathogens in plasma, platelet, and red 
cell products.17–19 The efficacy of UV light is limited only 
by its lack of penetration and its dependence on the distance 
from the light source. The cornea itself contains riboflavin 
already, but the concentration present is not enough to have 
antimicrobial effects in keratitis. The small amount of cor-
neal riboflavin present may become depleted on exposure 
to sunlight.20
Martins et al showed that a combination of UVA-
  riboflavin has antibacterial properties in vitro against micro-
organisms such as Pseudomonas aeruginosa, Staphylococcus 
aureus, Staphylococcus epidermidis, methicillin resistant 
Staphyloccus aureus, drug-resistant Streptococcus pneumo-
niae, and multidrug-resistant Pseudomonas aeruginosa.21 
Pathogen inactivation occurs via the byproducts of riboflavin 
after UVA exposure. Nucleic acids are damaged by direct 
electron transfer, production of singlet oxygen, and genera-
tion of hydrogen peroxide with the formation of hydroxyl 
radicals. Pathogen deoxyribonucleic acid (DNA)/RNA may 
even be affected in the absence of oxygen.22,23
Spoerl et al24 showed that porcine corneas which under-
went crosslinking were more resistant to the effects of pepsin, 
collagenase, and trypsin. Pepsin digested crosslinked eyes in 
13 days and untreated eyes in 6 days. Collagenase digested 
treated corneas in 14 days and untreated eyes in 6 days. 
Trypsin digested treated corneas in 5 days and untreated cor-
neas in 2 days. It is quite possible that part of the therapeutic 
effect of crosslinking in these cases was due to the decreased 
susceptibility of the corneal stroma to proteolytic enzymes 
produced by pathogenic bacteria.
The bactericidal and stromal strengthening properties of 
crosslinking make it a very attractive option for treating bacte-
rial keratitis, as has been shown in case series by other authors. 
Al-Sabai describes a case of keratitis due to Pseudomonas spp. 
in which crosslinking helped induce corneal cicatrization.8 
Iseli et al successfully crosslinked five patients with corneal 
melting due to infectious keratitis. Melting was arrested 
in all cases, with none requiring emergency keratoplasty.9 
Makdoumi et al treated seven eyes of six patients with severe 
infectious keratitis, with crosslinking causing an arrest of 
Figure  2  Appearance  of  case  2  (A)  at  initial  presentation,  (B)  1  week  after 
crosslinking  (note  the  cleaner  margins  and  decreased  infiltrate  density  of  the 
abscess), (C) 2 months after crosslinking (infiltration has been replaced by scar 
tissue; note the presence of an intrastromal hemorrhage), and (D) after penetrating 
keratoplasty combined with cataract extraction.
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melting and complete epithelialization in all cases, with a 
resolution of symptoms within 24 hours.10 Schnitzler reported 
that the treatment resulted in complete healing in two cases 
and delayed the need for surgery in another two cases.11 The 
findings of those case reports are mirrored in this current 
report, although the speed of resolution of these current cases 
was not as rapid as reported by Makdoumi et al.
In the bacterial infection, while fortified topical antibiotic 
therapy alone did not have the desired effect on the corneal 
abscess, the crosslinking led to a resolution of infection with 
an acceptable visual outcome, considering the location of 
the abscess.
The initial presentation of the fungal infection was clearly 
far more severe than that of the case of bacterial keratitis. 
The severity of the infection and the central location of the 
abscess caused scarring which limited the final visual acuity 
achieved. Penetrating keratoplasty was eventually required, 
but this was a more planned procedure in a less inflamed eye 
as compared with the therapeutic PKP which might have 
been performed in an acute setting.
In conclusion, UVA-riboflavin crosslinking could prove 
to be a valuable addition to our armamentarium for the treat-
ment of keratitis not responding to antimicrobial therapy. In 
addition, it allows us to delay therapeutic PKP procedures to 
a later date when they can be performed in a more controlled 
manner with a possibly lower risk of subsequent graft failure. 
However, until more data is available crosslinking should 
only be considered in keratitis resistant to treatment.
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